Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART19.1 in Pediatric R/R B-ALL
NCT03321123Phase 2Unknown
- Start
- Dec 2017
- Primary completion
- Jul 2019
- Modality
- CAR-T Cells
01
Overview
Phase 2, open-label trial of zorpocabtagene autoleucel in acute lymphoblastic leukemia (ALL). Primary endpoint: Overall Response Rate at 1 month. Status: unknown.
02
Drugs
zorpocabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03321123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03321123.